期刊文献+

2010-2012年重庆市34家医院抗肿瘤类国家基本药物利用分析

Consumption analysis of anti-cancer agents of national basic drugs in 34 hospitals in ChongQing during 2010-2012
下载PDF
导出
摘要 目的:了解2010-2012年重庆市抗肿瘤类国家基本药物的应用情况及发展趋势。方法:采用用药金额、DDDS、日均费用等为指标的分析方法,对重庆市34家医院2010-2012年抗肿瘤类国家基本药物的数据进行统计分析。结果:2010-2012年重庆市34家医院抗肿瘤基本药物用药总金额为14758.55万元;用药总金额年均下降6.66%;DDDS总体平稳;销售金额排名前10的药物日均费用逐年下降;在销售金额最大两个品种紫杉醇和奥沙利铂中,国企所占销售金额比有所降低。结论:通过以上分析,说明重庆市抗肿瘤类国家基本药物总体结构变化不大,总体销售金额、日均费用呈下降趋势。 Objective :To get a clear idea about the situation ,1evel of rationality and developing trend of use of anti -cancer agents of national basic drugs in ChongQing .Methods :The amount of medication ,DDDs sequencing and average daily cost of the anti -cancer agents used in 34 hospitals in ChongQing during 2010 -2012 were analysed .Results :Thirty four hospitals totally amount 147 .59 million yuan for anti-cancer agents of national basic drugs .Annual total amount decreased 6 .66% .DDDS generally stable .Daily expenses of the top 10 drugs decreased year by year .Conclusion :The situation of anti -cancer agents of national basic drugs in ChongQing changed little overall .The overall amount of sales and the average daily cost of anti -cancer agents of national basic drugs showed a downward trend .
出处 《激光杂志》 CAS CSCD 北大核心 2013年第5期120-122,共3页 Laser Journal
关键词 抗肿瘤 基本药物 趋势 用药分析 anti - cancer agents analysis trend national basic drugs
  • 相关文献

参考文献8

  • 1S. M. Lichtman. Global initiatives to enhance cancer care in areas of limited reoources. Am Soo Clin Oncol Educ Book, 2013,2013(411 - 413).
  • 2陈新谦,金有豫,汤光.新编药物学.17版.北京:人民卫生出版社,2011:609-621.
  • 3何苗苗,刘光斌,姜芳宁,谢六生.浅析临床药师对抗肿瘤药物的药学监护[J].肿瘤药学,2013,3(1):70-74. 被引量:19
  • 4王宁,袁延楠,郑荣寿,孙喜斌,王庆生,贺宇彤,陈万青.中国恶性肿瘤城乡发病差异分析[J].中国肿瘤,2013,22(3):168-173. 被引量:31
  • 5T. Brown, G. Pilkington, A. Bagust, et al. Clinical effectiveness and cost -effectiveness of first- line chemotherapy for adult patients with locally advanced or metastatic non- small cell lung cancer: a systematic review and economic evaluation.Health Technol Assess,2013,17(31) : 1 - 278.
  • 6W. X. Qi, z. Shen, F. Lin, et al. Paclirtel - based versus docetaxel - based regimens in metastatic breast cancer: a systematic review and meta- analysis of randomized controlled trials. Curt Med Res 0loin, 2013,29(2) : 117 - 125.
  • 7R. Pdem-sma, C. A. Forbes, M. M. Aroonkar, et al. Systematic review of lapatinib in combination with letrozole cored with other first - line treatments for hormone receptor positive (HR + ) and HER2 + advanced or metastatic breast cancer (MBC). Curt Med Res Opin, 2012,28(8) : 1263 - 1279.
  • 8R. Riemsma, C. A. Forbes, A. Kessels, et al. Systematic review of aromatase inhibitors in the first - line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res Treat, 2010, 123(1) :9 - 24.

二级参考文献20

  • 1刘群,王海莲.静脉化疗药物配制的影响因素及不良反应防治措施[J].中国药师,2007,10(1):83-84. 被引量:14
  • 2Henry DH,Spivak JL. Clinical use of erythropoietin[J].{H}Current Opinions in Hematology,1995,(02):118-124.
  • 3Hortodagyi GN,Frye D,Buzdar AU. Decreased cardiac toxicity of doxorubicin administered by continuos intravenous infusion in cobination chemotherapy for met-astatic breast carcinoma[J].{H}CANCER,1989,(01):37-45.
  • 4Muggia FM,Louie AC,Sikic BI. Pulmonary toxicity of an-titumor agents[J].{H}Cancer Treatment Reviews,1983,(04):221-243.
  • 5Cersosimo RJ. Cisplatin neurotoxicity[J].{H}Cancer Treatment Reviews,1989,(04):195-211.
  • 6卫生部合理用药专家委员会.MCDEX中国医师药师临床用药指南第1版[M]{H}重庆:重庆出版社,20094.
  • 7侯宁.临床静脉用药调配与配伍速查第1版[M]{H}北京:化学工业出版社,20121.
  • 8Bhargava P,Gammon D,McCormick MJ. Hypersensitivity and idiosyncratic reactions to oxaliplatin[J].{H}CANCER,2004,(01):211-212.
  • 9Gammon D,Bhargava P,McCormick MJ. Hypersensitivity reactions to oxalipatin and the application of a desensitiza-tion protocol[J].Oncol,2004,(05):546-549.
  • 10Williams C,Bryant A. Short versus long duration infusions of paclitaxel for any advanced adenocarcinoma[J].Co-chrane Database Syst Rev,2011,(05):CD003911.

共引文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部